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SOME results ofa current experiment in an investigation ofthe role ofendocrine
environment in tumorigenesis (Stern et al., 1965, 1967; Stern and Mickey, 1967) are
relevant to the study of long-term effects of anti-ovulatory drugs. Enovid was
administered to female Sprague-Dawley rats during appropriate stages of the
estrus cycle from age approximately 45 days until sacrifice. A single intragastric
ingestion of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) was given
at age 55 days.
Induction of mammary gland tumors by a single dose of a chemical carcinogen
as defined by Huggins et al. (1961) has served as a model for studying effects of
hormonal manipulation. Results from several laboratories appear to be consistent
with the findings of Huggins et al. (1962) that progesterone enhances mammary
gland tumnor induction, estrogen delays, and a progesterone-estrogen combination
inhibits the onset of tumors. Most of these findings are based on work with
chemically induced tumors. The similar response ofirradiation-induced mammary
gland tumors to hormone manipulation (Cronkite et al., 1960) and the hormonal
requirements of virus-associated preneoplastic mammary nodules (Blair et al.,
1962) suggest that the physiological interaction is largely independent of the
induction stimulus.
Results of administration of synthetic steroid antifertility compounds to
carcinogen-treated rats are not consistent, possibly because the experimental
protocols differed in the regimens of steroid and carcinogen administration.
Gruenstein et al. (1964) report no effect on incidence of chemically induced
mammary gland tumors while McCarthy (1965) reports an increased incidence
and Fletcher et al. (1965) refer to acceleration in both development and growth
of mammary gland tumors.
Although this study of the long-term effects of steroid antifertility agents is
still in progress, some interesting results are sufficiently clear to note at present.
There was a delayed onset of carcinogen-induced mammary gland tumors in
enovid-treated rats but no reduction in the final tumor incidence. Many of the
control animals developed palpable mammary gland tumors before any of the
enovid-treated animals did. As the experiment progressed, tumors developed in
the enovid-treated rats and by the end of the observation period, one year of age,
nearly all of the carcinogen-treated animals had developed mammary gland
tumors. However, there was a lower incidence of tumors of malignant potential
in the enovid rats as well as a shift in the relative frequency of malignant and
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METHOD
The current experiment differs from comparable ones in that the steroid
combination was given cyclically to simulate in Sprague-Dawley rats the regimen
of intermittent ingestion of steroid contraceptives in women. Administration
of the compound Enovid E* (EE) was begun at approximately 45 days of age,
soon after puberty. The dose was the same throughout the experiment consisting
of 1 mg. norethinodrel and 40 jug. mestranol in 1/2 ml. sesame oil given by gavage
before noon. The treatment schedule was regulated by daily vaginal smear
readings, taken at mid-morning and, for each cycle, treatment was begun at onset
of the preovulatory phase. This was taken as the day on which the vaginal
mucus became positive to the alcian-blue staint and in 5-day cycles, corresponded
to the second day of diestrus. The compound was withheld during estrus,
metestrus, and early diestrus to allow the maturation of a new set of follicles. A
normally cycling animal received the compound on 3 of 5 successive days.
Control animals were given the vehicle in a similar routine.
The carcinogen DMBA was administered in a single intragastric dose of 20 mg.
in 1 ml. of sesame oil to half of the rats at age 55 days, approximately 10 days
after beginning the cyclic steroid ingestion; the other animals received the oil
only. Necropsies were scheduled at ages 100, 200, and 365 days, after periods of
enovid treatment equivalent to 10, 30, and 60 cycles. In anattemptto standardize
observations to a single stage of the cycle, the animals were necropsied the day
after the proestrus ofthe cycle closest to the scheduled age.
Upon entry at age 21 days animals were assigned at random to treatment and
necropsy groups subject to a balanced representation of groups. Food and water
were available ad libitum. The environment was controlled and a 14 hour light-
10 hour dark schedule was maintained. The rats were housed four to a cage so
that all rats in a cage were treated alike; of the four, one was scheduled for
necropsy at age 100 days, one at 200 days, and two at 365 days. One hundred
and fifty-nine animals entered the study over a period of a year in 5 main cohorts
of size 68, 16, 25, 34, and 16 respectively.
From the day of vaginal opening, records of daily vaginal smears were main-
tained for all animals. Individual animal weights and the number and size of
mammary gland tumors were noted at a weekly observation.
At necropsy, under ether anesthesia, the animals were bled by cardiopuncture
and pituitary, adrenals, ovaries, uterus, liver and preputial glands were weighed.
Mammary glands were dissected and mammary gland tumors were removed,
measured and weighed. Histological sections were prepared on organsandtumors.
Comparable procedures were carried out post-mortem on animals which did not
survive to the designated necropsy date.
RESULTS
A delayed onset ofinduced mammary gland tumors was observed in the enovid-
treated rats. The time of onset and the extent of the delay were not consistent
* Norethinodrel (17x-ethynyl-17-hydroxy-5(10)-estren-3-one) 2-5 parts: Mestranol (ethynyles-
tradiol 3-methyl ether) 0-1 parts.
t The vaginal smears were stained by the alcian-blue, orange-G method. Alcian-blue identifies
the acid mucopolysaccharide produced in proestrus and is useful in distinguishing the nucleated cells
of proestrus which are AB-positive from the AB-negative nucleated cells of metestrus. Keratin
is stained yellow or red by this method. On the first day of diestrus there is an admixture of neutro-
philes and AB-negative mucus. The mucus becomes AB-positive on the second day of diestrus.
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among the 5 cohorts. However, the first 2, comprising the rats entering the
experiment in 1966, appeared to respond similarly; the last 3 cohorts entering in
1967, also responded similarly. The onset data were sorted on the basis of the
year of entry, and are listed in Table I and illustrated in Fig. 1. The plots of
Fig. 1 are based upon a life table type calculation in which allowance is made for
death, either by disease or by sacrifice, prior to onset oftumors.
The delayed tumor onset is considerably more pronounced in the rats acquired
the first half of the experiment. The time after DMBA treatment by which
fifty per cent (50%) of the rats developed tumors was 27 weeks for the enovid-
treated rats and 12-5 weeks for the corresponding controls. In the later cohort,
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FIG. I.-Delayed onset of mammary gland tumors in DMBA-treated rats receiving enovid
cyclically. Cohorts were nominally alike, but those entering the experiment in 1966 had a
noticeably more pronounced delay in tumor onset. Per cent with tumors adjusted for
mortality from other causes.
the time was 10-5 weeks for the enovid rats and 8 5 weeks for the controls. Since
all but one ofthe non-sacrifice deaths prior to tumor development occurred at age
less than 100 days and since only 4 rats survived to orbeyond age 200 days without
tumors, further statistical analysis was based on the time after DMBA treatment
oftumor onset for rats in the age 200 and 365 days necropsy groups. The results
were 22c 4 C 6o8weeks (mean a s.d.) (12 rats) and 11t9 e 4r4 weeks (12 rats)
for the enovid and control rats respectively in the earlier cohorts (t a4s51e
P <0t001); and 1208 ± 7-5 weeks (12 rats) and 852w 2k7 (15 rats) for the enovid
and control rays an sne onlyr rts (t = 2X00, P = 0b07; rank sum test with tied
ranks, Z = 1-98,P = 0-05).
Mammary gland tumors were classified in increasing order of malignant
potential asfibroadenoma, duct adenoma, papillary duct adenoma and carcinoma.
In Table fo, the distribution of tumor types is given for the control and enovid
rats treated with DMBA. Usually two or more tumor types were found in the
same animal, but an occasional animal developed only one type oftumor.
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TABLE I.-Delayed Onset of Mammary Gland Tumors in DMBA-treated Rats
Receiving Enovid Cyclically. Breakdown by Age at Onset, or Age at Death
if no Tumour, and by Cohorts
Cohorts of 1966 Cohorts of 1967
Age/days Age/days
Age/days at death Age/days at death
at tumor without at tumor without
onset tumor onset tumor
Enovid . 112 95* 98 100*
161 100 . 98 101
182 104 . 105 202
189 106 . 112
196 112 . 119
196 200 . 126
245 . 126
245 68t . 133 58t
252 318 133 61
252 . 140 61
259 . 167 67
266 . 203 83
- . 287
No. rats . 12 8 13 8
Control . 84 98* . 91 99*
105 98 . 91 99
119 100 91 197
126 106 . 91
126 . 91
140 . 98
147 - . 98
147 57t 112 57t
154 67 . 119 57
154 70 119 -
175 104 . 119
196 . 126 -
- . 133 -
133
140 -
- _- . 140
No. rats . 12 8 . 16 5
* Necropsy schedule death.
t Intercurrent death.
Among rats with tumors, I I of 28 (40%) of the controls and 7 of 24 (29%) of
the enovid animals developed mammary carcinoma. Lung metastases were found
in 4 of the control and 1 of the enovid animals. The proportions of the different
tumor types did not vary appreciably with age in the control group, but in the
enovid group only 1 in 7 ofthe 200 daynecropsy animals developed afibroadenoma
while fibroadenomas were present in 11 of 16 of the 365 days necropsy animals.
Since about 50% of the 200 day necropsy control group developed fibroadenomas
there appeared to be a delay in the rate of development of fibroadenomas in
enovid animals. Proportions ofother tumor types in enovid animals did not vary
with age; proportionsofanimalswithpapillarytumors andcancerswerecomparable
at both ages ofnecropsy in the enovid animals, and were lower than in the controls.
There is thus the suggestion of a shift in the relative frequency of benign and
394EFFECT OF CONTRACEPTIVE ON TUMOUR INDUCTION
TABLE II.-DMBA-induced Mammary Gland Tumors, Histological Types
Average Average No. rats Number of rats with
Groups by age at age at with , -A_ _A
age scheduled necropsy tumor No.* mammary Fibro- Duct Papillary Lung
forinecropsy or death onset rats tumor adenoma adenoma tumor Carcinoma metastasis
Enovid
100 . 100 98 8. 1 . 0 0 0 1 (1) 0
200 . 200 162 . 9 . 7 . 1(1) 5 (10) 1 (1) 2 (3) 0
365 . 310 . 193 18 . 16+±t 11 (48) 12 (25) 2 (4) 4 (7) 1
Totals . 35 . 25 12 (49) 17 (35) 3 (5) 7 (11) 1
Control
100 100 . 91 . 8. 1 . 0 0 1 (1) 0 0
200 . 200 . 142 .10. 9 5 (6) 7 (16) 2 (7) 3 (3) 0
365 . 293 120 .18 .18 9 (25) 14 (40) 4 (6) 8 (17) 4
Totals . 36 . 28 14 (31) 21 (56) 7 (14) 11 (20) 4
* Excluding rats with intercurrent deaths before age 84 days.
) Number in brackets is the total number of tumors.
t One animal with 3 palpable tumors was not available for necropsy.
malignant tumors with age as well as a modification in carcinogenic potential
of induced tumors in enovid-treated rats.
Milk secretion was present in some fibroadenomas and duct adenomas ofabout
one-third of control and enovid animals with mammary tumors and tended to
be relatively more prevalent in fibroadenomas of the older enovid animals.
Secretion was not present in papillary tumors and was only occasionally noted in
malignant tumors. One animal with mammary carcinoma showed secretion
in metastatic tumor nodules in the lung. Milk secretion was present in the
mammary gland tissue of all animals with mammary tumors. The differences
noted above are not statistically significant, but the trend is of sufficient interest
to merit notice.
One of the enovid: non-DMBA rats developed a mammary gland tumor of
the cystosarcoma phylloides type. The animal was 161 days old when the
tumor was found during the regular weekly examination of all animals and it was
removed surgically. None of the control: non-DMBA rats developed a tumor at
an age less than 365 days.
Results on organ weights reflect hormonal effects of the enovid and to a
lesser extent of the DMBA, together with an indication of the course of such
effects through time. The ovarian weights of the enovid rats were considerably
lower than controls at 100 days (59 mg. vs 107 mg., P < 0.01), but not at 200
days (85 mg. vs 90 mg.) nor at 365 days (85 mg. vs 82 mg.). Similar results
were observed for the DMBA-treated rats with the exception that at 200 days the
ovaries of the enovid: DMBA-treated rats were still low in comparison to
the enovid: non-DMBA rats (62 mg. vs 85 mg., P < 0-01). Uterus weights were
lower in enovid than in control groups at all three sacrifice ages (478 mg. vs 601 mg.
at 100 days, 592 mg. vs 713 mg. at 200 days and 634 mg. vs 802 mg. at 365 days;
P < 0-02 for each comparison). Similar results were observed for enovid and
control rats treated with DMBA. Uterus weights at 100 days were lower in
enovid: DMBA-treated rats in contrast to enovid: non-DMBA rats (390 mg
vs 478 mg., P < 0-01), but not at 200 days. Statistically significant differences
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among the treatment group means were not observed for pituitary weights. In
the case of the adrenals, the outstanding contrast was the increased weight in the
control: DMBA-treated rats when compared to control : non-DMBA rats at
200 days (73 mg. vs 63 mg., P < 0.01). Enovid vs control contrast of preputial
weights was statistically significant at age 100 days, but not at the later sacrifice
periods. Liver weights were significantly greater in the enovid than in control
rats at all necropsy periods.
Weekly body weight measurements reflect the effects of both the carcinogen
and the enovid treatments. The average daily weight gains for the period
55-60 days for the control animals were 2-95 and 1-64 g./day for the non-DMBA
and DMBA-treated rats respectively (t = 3-17, P = 0.002); corresponding rates
of gain for the enovid rats were 2-15 and 0-82 g./day (t = 3 04, P = 0.003). The
course of development reflected by body weight is summarized in Table III.
TABLE III. Average Weights of Rats
Age/days CV CD EV ED
35 . 127-8 ± 13-1a 1251 -4- 17-7 . 123-9 ± 14-6 124-1 ± 14-1
38b . 41 39 . 41
55 . 213-2 ± 14-9 210-0 >- 14-4 191-4 ± 15-3 . 193-2 ± 15-2
37 . 37 . 38 . 37
91 . 282-8 ± 17-2 . 269-1 ± 18-2 . 242-4 ± 16-0 . 240-1 + 13-8
38 . 35 38 35
196 . 324-9 ± 21-8 . 317-5 ± 17-3 . 285-5 ± 16-4 . 273-1 ± 18-0
29 . 24 . 30 . 26
a = standard deviation.
b = number of rats.
CV = control non-DMBA.
CD = control DMBA-treated.
EV = enovid non-DMBA.
ED = enovid DMBA-treated.
The altered growth pattern ofenovid-treated rats, as reflected by body weights,
was very clear and was characterized by fitting an empirical growth curve to
the group average weights over the age range 49-196 days. The curve fitted
was:
w(t) - W lT
1 + (t/T50)a
in which w(t) is the mean weight at age t, W is the limiting weight, T50 is the age
at which half of the limit is attained, and a is a parameter characteristic of the
rate of growth. The fitted curves are quite representative of the data; the root
mean square deviations are 1-6 g. and 2-1 g. forthe non-DMBA control and enovid
groups respectively.
The values ofthe constants determined for the non-DMBA control and enovid
groups were:
Control: W = 339 g. = 211 T50 42-9 days
Enovid: W = 308 g. c= 1953 T50 39-4 days
The constant W represents a limiting weight, and the results reflect the lowered
body weight of the mature enovid-treated rats in comparison with the control
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animals. The lower value ofa for the enovid-treated rats reflects a slower rate of
growth.
The results of fitting the DMBA-treated rats were somewhat less satisfactory
in that the growth pattern is disturbed shortly after ingestion of DMBA, and that
in the older tumor bearing rats, the pattern of weight increase can be dominated
by tumor growth. In the enovid-treated rats the growth pattern of the DMBA
rats was similar to that of the non-DMBA animals in that the values of a and
T50 were essentially the same, while W was decreased (to 300 g.). In the DMBA-
treated control group, the value of a was reduced (to 1.74), which is interpreted
mainly as a reflection of tumor growth in the older animals.
It is beyond the scope of this project to consider the possible physiological
significance of the altered growth pattern accompanying enovid treatment.
It may nonetheless be of interest to adjust the tumor onset times in the enovid-
treated rats to the time scale ofthe control rats. The adjusted time was computed
as:
t = 3 45(t)0°693
the numerical results for the two parts of the experiment were as follows:
Onset Time, Days, Adjusted to Growth Scale of Control Rats
Standard
error of
Cohorts Enovid Control difference P
1966 140-0 139-0 10.5 0*92
1967 106*9 113-4 8-8 0 45
In a sense, the adjusted time scale " accounts for " the increased latency. The
results are as though the enovid treatment resulted in a slower biological aging.
DISCUSSION
The endocrine environment studied was that resulting from cyclic administra-
tion of the antifertility agent Enovid E. The enovid was given in a routine
corresponding to that followed in human use. The literature pertaining to effect
of hormonal environment on initiation and development of cancer does not
provide a clear guide to anticipation of results of experiments such as the one
reported here. The finding of Huggins et al. (1962) that a progesterone-estrogen
combination (progesterone 4 mg.-estradiol 17,/, 20 ug.) inhibits mammary gland
tumor induction in DMBA-treated female rats whereas progesterone by itself
increases and estrogen delays tumor development suggests that a somewhat
delicate balance may be involved, and the effects may depend critically on the
particular compounds used, their dosage and the regimen followed in their
administration.
This possible sensitivity was noted by Hertz and Bailar (1966) in discussing
the effect of steroid antifertility agents in humans and may account for the
apparent disparity in results of some experiments on the effect of antifertility
compounds on the induction ofmammary gland tumors. For example, McCarthy
(1965) found an increased incidence of mammary cancer in Sprague-Dawley rats
treated with 0 25 mg. eitherofenovid ornorlestrin daily for 10dayspriorto asingle
feeding of 8 mg. DMBA, while no difference was found using the larger dosage of
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1 mg. daily of the antifertility compounds. On the other hand, Weisburger
et al., (1968) feeding 0 3 or 3 mg. of enovid daily for 45 days beginning 10 days
before a single administration of 15 mg. of DMBA report a decreased incidence of
induced mammary cancer, the inhibition effect being more marked at the higher
dose level. No difference in tumor incidence between control and enovid-treated
animals was reported by Gruenstein et al. (1964) when they treated Wistar rats
for one year with 2-5 mg. 3-methyleholanthrene and 3 mg. enovid given 6 days a
week, although the data in that report shows a lengthened onset in the enovid-
treated animals.
In our experiment, the delay in onset of induced mammary gland tumors in
enovid-treated rats may be related to the finding of significant differences between
enovid and non-enovid rats in endocrine and target organs. The differences
are greater in animals necropsied at age 100 days than at ages 200 and 365 days.
This early alteration in the internal hormonal environment of enovid rats at a
time when induced tumors are beginning to develop in control animals may be
related to the latency in development and modification of carcinogenic potential
of tumors in enovid-treated animals.
In previous work, we found a significant drop in the incidence of carcinogen-
induced mammary gland tumors in androgen-sterilized rats. In these animals,
the hormonal disturbance provides an internal environment in which the induction
of mammary carcinoma is inhibited while the development of ovarian granulosa
cell tumors is favored (Stern et al., 1967).
Androgen-sterility results following a single post-natal injection of testosterone
(Barraclough, 1961). The hormonal state in the androgen-sterile rat is one in
which ovulation is blocked by impairment of the hypothalamic regulation of
pituitary function (Barraclough and Gorski, 1961). Cyclic release of lutenizing
hormone (LH) is blocked and factors controlling the release of prolactin (LTH)
are modified. When adult, the animals are sterile, corpora lutea are absent from
the ovaries, but there is maturation of graafian follicles. The mammary glands
(Stern et al., 1965) show patchy lobuloalveolar development and secretion.
A comparable hormonal state is obtained by administration of steroid anti-
fertility compounds. As in androgen-sterility, the antifertility effect is due to
suppression of ovulation by means of a primary action on the hypothalamus.
Holmes and Mandl (1962) induced functional sterility in rats using norethinodrel
and reported complete absence of or a reduction in the number of corpora lutea.
Although ovulation is not consistently blocked, there appears to be suppression
of pituitary LH. In women the progestogen-estrogen combinations inhibit the
LH peak (World Health Organization, 1965). Minaguchi and Meites (1967) report
that in rats, enovid reduces the prolactin-inhibiting factor (PIF) content of the
hypothalamus presumably promoting prolactin secretion by the pituitary. Stimu-
lation of lobulo-alveolar development and secretory activity in mammary glands
was reported by Kahn and Baker (1964).
The similarity of hormonal states of the androgen-sterile rats and enovid-
treated rats provides a basis for anticipating similar carcinogenic response to
DMBA. In both cases there is inhibition ofcarcinogen-induced mammary tumors.
In the enovid experiment, animals were observed over a period of one year and
the inhibition is manifest as increased latency while in the case of the androgen-
sterile experiment, terminated at age 150 days, inhibition is indicated by decreased
incidence.
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The development of a mammary tumor in one of the 18 enovid: non-DMBA
rats, at age 161 days, is potentially a result of considerable interest. This is
particularly the case in view of the concern that a possible hyperestrogenic state
resulting from prolonged use of steroid antifertility compounds might result in
increased mammary cancer (Hertz and Bailar, 1966). Although we have not
previously observed mammary cancer in control animals under one year of age,
this single occurrence is not so exceptional as to support conclusions of substance.
Increased weight of the liver was present at all ages of necropsy in the enovid
animals. There is no evidence that in this respect animals adapt to the treatment
and the change appears to be cumulative.
The possibility ofa relationship ofdelayed tumor onset with the slower growth
of the enovid-treated rats exists, but is no more than suggested here. The
decreased growth rate has been noted in all of the experiments using steroid
antifertility compounds referenced. Pincus (1966) ascribed the lower body weight
to inhibition ofproduction or release ofgrowth hormone. In either case, there is
evidence of action of the compounds at the level of the central nervous system.
We have come to regard such action, particularly in the hypothalamus, as relevant
to cancer induction and development (Stern and Mickey, 1967; Stern, Mickey and
Gorski, 1969).
SUMMARY
A steroid antifertility combination was administered cyclically to female rats
in order to simulate the intermittent schedule oforal contraception used by women.
There were alterations in endocrine and target organs which were more
evident after the equivalent of 10 cycles of treatment than after 30 or 60 estrus
cycles. The enovid rats also experienced an altered growth pattern.
Following a single dose ofthe carcinogen DMBA there was a latency in develop-
ment, and modified carcinogenic potential, of induced mammary tumors. The
latency was accounted for by the slower rate ofgrowth ofthe enovid animals.
The modified carcinogenic response may be related to the early alteration
in internal hormonal environment associated with the enovid treatment.
We thank G. D. Searle and Co. for their generous gift ofEnovid E.
This study was supported by a research grant from the N.I.H., C.H.H.D.
Assistance was obtained from the Health Sciences Computing Facility-
UCLA, sponsored by N.I.H. grant FR-3.
REFERENCES
BARRACLOUGH, C. A.-(1961) Endocrinology, 68, 62.
BARRACLOUGH, C. A. AND GORSKI, R. A.-(1961) Endocrinology, 68, 68.
BLAIR, P. B., DEOME, K. B., AND NANDI, S.-(1962) In 'Biological Interactions in
Normal and Neoplastic Growth'. Edited by Brennan and Simpson. Boston
(Little, Brown & Co.).
CRONKITE, E. P., SHELLABARGER, C. J., BOND, V. P. AND LIPPINCOTT, S. W.-(1960)
Radiat. Res., 12, 81.
FLETCHER, W. S., MCSWEENEY, E. D. JR, AND DUNPHY, J. E.-(1965) J. Am. med. Ass.,
191, 116.
GRUENSTEIN, M., SHAY, H., AND SHIMKIN, M. B.-(1964) Cancer Res., 24, 1656.
HERTZ, Roy, AND BAILAR, J. C.-(1966) J. Am. med. Ass., 198,136.400 ELIZABETH STERN AND M. R. MICKEY
HOLMES, R. L. AND MANDL, A. M.-(1962) J. Endocr., 24,497.
HUGGINS, C., GRAND, L. C. AND BRILLANTES, F. P.-(1961) Nature, Lond., 189, 204.
HUGGINS, C., MOON, R. C. AND MORII, S.-(1962) Proc. natn. Acad. Sci. U.S.A., 48, 379.
KAHN, R. H. AND BAKER, B. L.-(1964) Endocrinology, 75, 818.
MCCARTHY, D.-(1965) Am. J. Surg., 110, 720.
MINAGUCHI, H. AND MEITES, J.-(1967) Endocrinology, 81, 826.
PINCUS, G.-(1966) Science, N.Y., 153, 493.
STERN, E. AND MICKEY, M. R.-(1967) Nature, Lond., 216, 185.
STERN, E., MICKEY, M. R. AND GORSKI, R.-(1969) Ann. N.Y. Acad. Sci. (In press).
STERN, E., MICKEY, M. R. AND OSVALDO, L.-(1965) Nature, Lond., 206, 369.-(1967)
Rass. Neurol. veg. XXI, fasc. 1-2.
WEISBURGER, J. H., WEISBURGER, E. K., GRISWOLD, D. P. JR. AND CASEY, A. E.-(1968)
Life Sci., 7, 259.
WORLD HEALTH ORGANIZATION.-(1965) Tech. Rep. Ser. Wld Hlth Org., 303, 16.